Bristol Myers Squibb (BMS) and Jiangsu Hengrui Pharmaceuticals (Hengrui) sign a global collaboration and licensing agreement valued at up to $15.2 billion, according to multiple reports. Bloomberg and STAT describe the deal as covering early-stage development work that BMS uses to tap into efficiencies in China’s research pipeline. STAT adds that the partnership advances more than a dozen early-stage drugs. The South China Morning Post reports the agreement is for a global collaboration and licensing arrangement and notes it is worth up to $15.2 billion. The Next Web specifies that the pact includes 13 early-stage drug programmes across oncology, haematology and immunology, and that none of the drugs have entered human clinical trials. The outlets also report market reaction to the announcement, including gains in Hengrui shares in Hong Kong and Shenzhen. Overall, the sources agree on the counterparties, the maximum deal value, and that the focus is early-stage drug programmes under a licensing and collaboration framework.
Bristol Myers Squibb signs up-to-$15.2 billion deal with Hengrui Pharma
Bristol Myers Squibb (BMS) and Jiangsu Hengrui Pharmaceuticals (Hengrui) sign a global collaboration and licensing agreement valued at up to $15.2 billion, according to multiple reports. Bloomberg and...
- Bristol Myers Squibb (BMS) signs a global collaboration and licensing deal with Jiangsu Hengrui Pharmaceuticals.
- The deal is valued at up to $15.2 billion.
- The agreement focuses on advancing early-stage drug programmes; one report says 13 programmes.
- The drug areas cited include oncology, haematology, and immunology.
- Shares of Hengrui rise after the announcement in Hong Kong and Shenzhen.
Bristol Myers Squibb has signed a deal worth up to 15.2 billion dollars with Jiangsu Hengrui Medicine, China’s largest pharmaceutical company by market capitalisation. The agreement covers 13 early-stage drug programmes across oncology, haematology, and immunology. None of the drugs have entered human clinical trials. The deal was announced on the same day that […] This story continues at The Next Web
3 months agoJiangsu Hengrui Pharmaceutical, China’s largest drug company by market capitalisation, has signed a global collaboration and licensing agreement with US pharmaceutical giant Bristol Myers Squibb (BMS) worth up to US$15.2 billion. Hengrui’s Hong Kong-traded shares climbed 5.3 per cent to HK$69.55 on Tuesday, while its Shenzhen stock rose 4.84 per cent to 56.11 yuan. The deal adds credibility to China’s growing reputation for innovative drug development. Industry players, however, said the country...
3 months agoBristol Myers Squibb and China's Hengrui Pharma are teaming up to advance more than a dozen early-stage drugs, in a deal worth up to $15.2 billion.
3 months agoBristol-Myers Squibb Co. inked a collaboration and licensing deal with Jiangsu Hengrui Pharmaceuticals Co. that could be valued at as much as $15.2 billion, as the US drugmaker seeks to leverage China’s efficiency in early development.
3 months ago
Procam launches “HDOR – 100 Days of Running” programme to build long-term movement habits
Procam launches “HDOR – 100 Days of Running”, a programme aimed at turning 100 days of running or movement into lasting...
Nepal flood victims’ families search Kathmandu hospitals for missing relatives
Families affected by floods in Nepal search Kathmandu hospitals for relatives who are missing, hoping they may still be...
Sam Ehlinger leads Broncos to 34-6 preseason win over Vikings
The Denver Broncos beat the Minnesota Vikings 34-6 in their preseason finale on Friday night, with quarterback Sam Ehlin...